![[Video] The Weekly Break Out Ep. 20: Pacific policy in Singapore and the UK’s new defense plan](https://breakingdefense.com/wp-content/uploads/sites/3/2025/06/Break-Out-ep-20-thumb-Play-Button.jpg?#)
STAT+: Kymera reports early-stage success for drug meant to rival Sanofi and Regeneron’s Dupixent
Kymera Therapeutics reported that an experimental drug designed to rival Sanofi and Regeneron’s blockbuster therapy Dupixent succeeded in a closely watched early-stage trial.
Kymera Therapeutics on Monday reported that an experimental drug designed to rival Sanofi and Regeneron’s blockbuster therapy Dupixent succeeded in a closely watched early-stage trial.
The Phase 1 trial, which enrolled 118 healthy volunteers, tested the safety and tolerability of KT-621, a small molecule drug that targets STAT6, a signaling protein that plays a key role in driving immune activation. The study found that the experimental therapy was as safe as the placebo, with no severe adverse events and no treatment-related adverse events that caused participants to stop taking the drug.
Researchers also evaluated STAT6 protein levels in participants’ skin and blood after treatment. They found that all doses of KT-621 above 1.5 mg led to more than 90% degradation of STAT6 in the blood and that doses of 50 mg or higher led to complete degradation of the protein in skin or blood.
